Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 47, Issue 3, 2012, Pages 463-464

  Nakamura, D ^a   Yoshimitsu, M ^a   Kawada, H ^a   Inoue, H ^a   Kuroki, T ^a   Kaieda, T ^a,b   Fujino, S ^a   Hamada, H ^a,b   Suzuki, S ^a,b   Matsushita, K ^a,b   Uozumi, K ^a,b   Arima, N ^a,b  

^a KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBIN; BILIRUBIN; BUSULFAN; CYCLOPHOSPHAMIDE; FIBRINOGEN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PROSTAGLANDIN E1; RECOMBINANT THROMBOMODULIN; TACROLIMUS;

ABDOMINAL TENDERNESS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; CASE REPORT; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEPATIC SINUSOIDAL OBSTRUCTIVE SYNDROME; HUMAN; JAUNDICE; LETTER; LIVER DISEASE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOMODULIN; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84858082332     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.103     Document Type: Letter

References (9)

1. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
2. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501-1506. (Pubitemid 27097440)
3. Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006; 91: 795-800. (Pubitemid 44014546)
4. Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84: 724-730. (Pubitemid 23248068)
5. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe venoocclusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343. (Pubitemid 35429671)
6. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41. (Pubitemid 44921064)
7. Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 783-785.
8. Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1983; 49: 265-275. (Pubitemid 14202230)
9. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267. (Pubitemid 23046384)